Table 3.
Differences From Baseline Values at T1 and T2a.
| AT | MT | P b | CT | P c | |
|---|---|---|---|---|---|
| EORTC Physical Functioning | |||||
| T1-T0 | −1.7 (16.1) | 11.9 (12.0) | .005 | 9.7 (14.9) | .007 |
| T2-T0 | −2.6 (14.5) | 11.6 (14.6) | .012 | 5.1 (6.8) | .186 |
| EORTC Role Functioning | |||||
| T1-T0 | 3.0 (20.9) | 19.5 (29.2) | .061 | 14.2 (27.8) | .178 |
| T2-T0 | −1.3 (17.3) | 20.4 (25.5) | .014 | 6.3 (31.0) | .185 |
| EORTC Emotional Functioning | |||||
| T1-T0 | −0.7 (16.8) | 14.9 (20.1) | .039 | 10.6 (24.4) | .193 |
| T2-T0 | −10.9 (22.4) | 13.5 (21.1) | .002 | 3.6 (25.2) | .072 |
| EORTC Cognitive Functioning | |||||
| T1-T0 | 13.9 (13.9) | 13.2 (22.4) | .513 | 11.8 (19.1) | .772 |
| T2-T0 | −2.6 (23.4) | 12.8 (25.1) | .034 | 10.4 (19.0) | .120 |
| EORTC Social Functioning | |||||
| T1-T0 | 8.4 (29.7) | 12.7 (25.8) | .239 | 14.2 (27.0) | .369 |
| T2-T0 | 1.3 (25.0) | 14.1 (26.5) | .045 | 3.1 (30.1) | .528 |
| EORTC Global Health Status | |||||
| T1-T0 | 13.9 (22.8) | 10.1 (18.8) | .934 | 9.4 (18.9) | .855 |
| T2-T0 | 5.1 (19.4) | 9.0 (20.1) | .421 | 3.2 (22.8) | .767 |
| EORTC Fatigue | |||||
| T1-T0 | −10.2 (18.6) | −20.3 (21.2) | .193 | −17.2 (21.1) | .268 |
| T2-T0 | −0.9 (23.8) | −20.6 (22.1) | .012 | −11.1 (26.1) | .149 |
| EORTC Nausea/Vomiting | |||||
| T1-T0 | 0.0 (7.1) | −1.2 (11.8) | .603 | −2.8 (12.9) | .709 |
| T2-T0 | 7.7 (14.6) | −0.6 (15.0) | .716 | 1.8 (22.1) | .872 |
| EORTC Pain | |||||
| T1-T0 | 2.8 (22.3) | −8.6 (17.0) | .119 | −1.2 (25.9) | .509 |
| T2-T0 | 5.1 (24.9) | −11.7 (33.0) | .119 | 3.1 (35.5) | .473 |
| EORTC Dyspnea | |||||
| T1-T0 | −3.0 (31.5) | −10.3 (26.9) | .949 | −9.8 (35.2) | .956 |
| T2-T0 | −2.8 (26.4) | −11.1 (29.3) | .432 | −16.7 (30.4) | .114 |
| EORTC Insomnia | |||||
| T1-T0 | −5.6 (27.8) | −32.2 (33.9) | .012 | −20.8 (28.9) | .075 |
| T2-T0 | −10.3 (21.1) | −33.3 (32.0) | .019 | −22.9 (34.1) | .061 |
| EORTC Appetite Loss | |||||
| T1-T0 | 2.8 (9.6) | −6.9 (22.5) | .345 | −4.1 (28.1) | .604 |
| T2-T0 | 10.3 (31.6) | −6.2 (26.2) | .561 | 3.6 (32.2) | .846 |
| EORTC Constipation | |||||
| T1-T0 | 0.0 (0.0) | −3.5 (24.1) | .538 | −0.8 (17.4) | .602 |
| T2-T0 | 5.1 (12.5) | 6.4 (23.1) | .334 | 6.3 (25.9) | .615 |
| EORTC Diarrhea | |||||
| T1-T0 | 6.1 (29.1) | −1.1 (33.9) | .818 | 1.7 (26.1) | .829 |
| T2-T0 | 13.9 (22.3) | −3.8 (28.8) | .133 | 4.5 (30.6) | .526 |
| EORTC Financial Problems | |||||
| T1-T0 | 8.3 (25.1) | −13.8 (30.2) | .047 | −3.3 (25.9) | .553 |
| T2-T0 | 12.8 (32.0) | −14.1 (28.6) | .028 | 0.9 (21.8) | .421 |
Abbreviations: AT, aerobic training; MT, multimodal therapy; CT, combination therapy; EORTC, European Organisation for Research and Treatment of Cancer.
a
Table shows the mean differences (± standard deviation) from T0 to T1 or T2 for the EORTC dimensions and the P values for the test for superiority of MT and CT over AT. All results are displayed for both T1 and T2 and are based on the imputed data set with missing value.
b
P values of the van-Elteren test stratified for preference/randomization for difference between MT versus AT.
c
P values of the van-Elteren test stratified for preference/randomization for difference between CT versus AT.
P values in boldface indicate statistically siginificance.